Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer. The therapies are based on the company's unique understanding of galectin proteins, which are key mediators of biological and pathologic functions.
The company reported today that it had hired Rex Horton as Executive Director of Regulatory Affairs and Quality Assurance. Mr. Horton is an experienced industry professional with 20 years of management and leadership experience in global regulatory matters including drugs, biologics, and vaccines. He has expertise spanning preclinical development through new drug approvals in a number of diverse therapeutic areas.
Horton most recently was Director of Regulatory Affairs at Chelsea Therapeutics where he successfully led the company through its first NDA filing and favorable FDA advisory committee meeting. In prior leadership roles at Solvay Pharmaceuticals and Abbott Laboratories, he led approval efforts for key products including Androgel Stickpack, Creon Capsules, and Luvox CR Capsules.
Galectin Therapeutics' appointment of Mr. Horton comes at a crucial time for the company. It is at a pivotal stage in its development of carbohydrate compounds for the treatment of cancer and liver fibrosis. The company is poised to submit an IND for GR-MD-02 for treatment of non-alcoholic steatohepatitius (NYSEARCA:NASH) with fibrosis and expects to begin a Phase 1 clinical trial in early in 2013.
For additional information about Galectin Therapeutics and its novel treatments pipeline, please visit galectintherapeutics.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net